Prevention of Progression in Chronic Liver Disease -

Prevention of Progression in Chronic Liver Disease

An Update on SNMC (Stronger Neo-Minophagen C). In honour of Hans Popper's 100th birthday

N. Hiyashi, M.P. Manns (Herausgeber)

Buch | Hardcover
130 Seiten
2004
Springer (Verlag)
978-0-7923-8796-1 (ISBN)
106,99 inkl. MwSt
In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression.
In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.

List of Principal Authors.- Preface. Introduction.- 1: Mechanisms of fibrogenesis.- 2: Non-invasive markers of liver injury.- 3: Complications of cirrhosis: the relevance of hepatocellular carcinoma.- 4: Controlling necroinflammation of liver with SNMC (Stronger Neo Minophagen C): therapy on interferon non-responders.- 5: Predictive parameters of non-response to standard hepatitis treatment.- 6: Concepts for the treatment of non-responders in hepatitis.- 7: Glycyrrhizin: the molecule and present knowledge of action in various liver diseases.- 8: Dendritic cells in immune responses against hepatitis C virus.- 9: SNMC in the prevention of cirrhosis and hepatocellular carcinoma: Japanese experience.- 10: SNMC in interferon non-responders with chronic hepatitis C: European experience in controlled trials.- Index.

Erscheint lt. Verlag 21.7.2004
Reihe/Serie Falk Symposium ; 138A
Zusatzinfo VIII, 130 p.
Verlagsort Dordrecht
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizinische Fachgebiete Innere Medizin Hepatologie
Medizin / Pharmazie Studium
ISBN-10 0-7923-8796-1 / 0792387961
ISBN-13 978-0-7923-8796-1 / 9780792387961
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Diagnostik, Differenzialdiagnostik, Therapieansätze

von Frank Fischbach; Katharina Fischbach

Buch (2016)
Thieme (Verlag)
101,00